These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 21969004)

  • 1. Hepatitis B virus mutants associated with hepatitis B surface antigen loss: chicken or egg?
    Tseng TC; Kao JH
    Hepatology; 2012 Feb; 55(2):656-7. PubMed ID: 21969004
    [No Abstract]   [Full Text] [Related]  

  • 2. Commentary on emergence of hepatitis B virus S gene mutants in patients experiencing HBsAg seroconversion after peginterferon therapy.
    Jazayeri SM; Alavian SM
    Hepatology; 2011 Nov; 54(5):1889; author reply 1889-90. PubMed ID: 21898500
    [No Abstract]   [Full Text] [Related]  

  • 3. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes.
    Houlihan DD; Hopkins LJ; Suresh SX; Armstrong MJ; Newsome PN
    Hepatology; 2011 Nov; 54(5):1891-2; author reply 1892. PubMed ID: 21987440
    [No Abstract]   [Full Text] [Related]  

  • 4. Emergence of hepatitis B virus S gene mutants in patients experiencing hepatitis B surface antigen seroconversion after peginterferon therapy.
    Hsu CW; Yeh CT
    Hepatology; 2011 Jul; 54(1):101-8. PubMed ID: 21503942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting treatment outcomes for HBV patients.
    AIDS Patient Care STDS; 2009 Mar; 23(3):223. PubMed ID: 19480059
    [No Abstract]   [Full Text] [Related]  

  • 6. Occult hepatitis B virus infection in patients with chronic hepatitis C: An actor behind the scene or just a bystander?
    Chu CJ; Lee SD
    J Gastroenterol Hepatol; 2010 Feb; 25(2):221-3. PubMed ID: 20136983
    [No Abstract]   [Full Text] [Related]  

  • 7. Peginterferon for chronic hepatitis B: predicting success with on-treatment benchmarks.
    Moucari R
    J Gastroenterol Hepatol; 2010 Sep; 25(9):1474-5. PubMed ID: 20796141
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
    Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
    J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical analysis of seroconversion of HBsAg in chronic hepatitis B patients treated with PegIFN alpha-2a].
    Yang F; Wu XF; Li XH; Wei N
    Zhonghua Gan Zang Bing Za Zhi; 2009 Dec; 17(12):950-1. PubMed ID: 20038343
    [No Abstract]   [Full Text] [Related]  

  • 11. Hepatitis B viral factors and treatment responses in chronic hepatitis B.
    Lin CL; Kao JH
    J Formos Med Assoc; 2013 Jun; 112(6):302-11. PubMed ID: 23787007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Commentary: HBsAg levels as predictor of sustained response to peg interferon in HBeAg-negative chronic hepatitis B.
    Hadziyannis SJ
    Aliment Pharmacol Ther; 2012 Apr; 35(7):842-3; discussion 843-4. PubMed ID: 22404402
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously.
    Cheng HR; Kao JH; Wu HL; Chen TC; Tseng TC; Liu CH; Su TH; Chen PJ; Chen DS; Liu CJ
    Liver Int; 2014 Jul; 34(6):e71-9. PubMed ID: 24119014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?
    Janssen HL; Sonneveld MJ; Brunetto MR
    Gut; 2012 May; 61(5):641-5. PubMed ID: 22180061
    [No Abstract]   [Full Text] [Related]  

  • 15. Hepatitis B virus genotypes: "clinical & therapeutic implications".
    Khawaja RA; Khawaja AA
    J Pak Med Assoc; 2009 Feb; 59(2):101-4. PubMed ID: 19260575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Quantification of hepatitis B virus HBsAg: clinical implications].
    Buti M; Rodríguez Frías F; Esteban R
    Med Clin (Barc); 2012 Apr; 138(11):483-8. PubMed ID: 21719049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B.
    Sonneveld MJ; Arends P; Boonstra A; Hansen BE; Janssen HL
    J Hepatol; 2013 May; 58(5):898-903. PubMed ID: 23376362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B.
    Tangkijvanich P; Komolmit P; Mahachai V; Sa-nguanmoo P; Theamboonlers A; Poovorawan Y
    J Clin Virol; 2009 Oct; 46(2):117-23. PubMed ID: 19651540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The summarized of EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.
    Idilman R
    Turk J Gastroenterol; 2017 Sep; 28(5):412-416. PubMed ID: 28936972
    [No Abstract]   [Full Text] [Related]  

  • 20. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a.
    Moucari R; Martinot-Peignoux M; Mackiewicz V; Boyer N; Ripault MP; Castelnau C; Leclere L; Dauvergne A; Valla D; Vidaud M; Nicolas-Chanoine MH; Marcellin P
    Antivir Ther; 2009; 14(8):1183-8. PubMed ID: 20032548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.